Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2025 | $80.00 | Neutral → Buy | Citigroup |
| 5/27/2025 | Hold | Needham | |
| 3/3/2025 | Buy → Hold | Argus | |
| 2/6/2025 | $80.00 → $75.00 | Outperform → Market Perform | Leerink Partners |
| 2/3/2025 | Buy → Hold | Needham | |
| 12/13/2024 | Peer Perform | Wolfe Research | |
| 12/10/2024 | $90.00 | Buy | Needham |
| 12/10/2024 | $85.00 | Hold | Jefferies |
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
3 - HOLOGIC INC (0000859737) (Issuer)
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2025 on Wednesday, July 30, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (866) 400-0049 (in the United States and Canada) or +1 (313) 209-4906 (for international callers) and referencing access code 5212316. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.holog
Completed assessment of more than 2,800 patients highlights the profound impact of the test in helping to predict the likelihood of extended endocrine therapy benefit for patients with HR+ breast cancer to support more informed care decisions Hologic, Inc. (NASDAQ:HOLX) and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating the significant clinical impact of the Breast Cancer Index® (BCI®) test, which will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025. "These data highlight the critical role the Breast Cancer Index test plays in guiding extended endocrine therapy decisions for women with early-stage, hormone
– Revenue of $1,005.3 Million Slightly Exceeds Guidance – – Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal second quarter ended March 29, 2025. "We delivered on our financial commitments in the second quarter," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share
For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod
For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump
Citigroup upgraded Hologic from Neutral to Buy and set a new price target of $80.00
Needham reiterated coverage of Hologic with a rating of Hold
Argus downgraded Hologic from Buy to Hold
8-K - HOLOGIC INC (0000859737) (Filer)
SD - HOLOGIC INC (0000859737) (Filer)
10-Q - HOLOGIC INC (0000859737) (Filer)
4 - HOLOGIC INC (0000859737) (Issuer)
Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi
Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2025 on Wednesday, July 30, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (866) 400-0049 (in the United States and Canada) or +1 (313) 209-4906 (for international callers) and referencing access code 5212316. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.holog
– Revenue of $1,005.3 Million Slightly Exceeds Guidance – – Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal second quarter ended March 29, 2025. "We delivered on our financial commitments in the second quarter," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2025 on Thursday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 6553890. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.hologic.c
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)